JP2021525775A5 - - Google Patents

Info

Publication number
JP2021525775A5
JP2021525775A5 JP2020567530A JP2020567530A JP2021525775A5 JP 2021525775 A5 JP2021525775 A5 JP 2021525775A5 JP 2020567530 A JP2020567530 A JP 2020567530A JP 2020567530 A JP2020567530 A JP 2020567530A JP 2021525775 A5 JP2021525775 A5 JP 2021525775A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
formula
compound
Prior art date
Application number
JP2020567530A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019234402A5 (https=
JP7402826B2 (ja
JP2021525775A (ja
Filing date
Publication date
Priority claimed from GB1809113.2A external-priority patent/GB2575623B/en
Application filed filed Critical
Publication of JP2021525775A publication Critical patent/JP2021525775A/ja
Publication of JPWO2019234402A5 publication Critical patent/JPWO2019234402A5/ja
Publication of JP2021525775A5 publication Critical patent/JP2021525775A5/ja
Application granted granted Critical
Publication of JP7402826B2 publication Critical patent/JP7402826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567530A 2018-06-04 2019-06-03 がん悪液質において用いる化合物 Active JP7402826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1809113.2A GB2575623B (en) 2018-06-04 2018-06-04 3-hydroxybutyrate esters for treating cancer cachexia
GB1809113.2 2018-06-04
PCT/GB2019/051532 WO2019234402A1 (en) 2018-06-04 2019-06-03 Compounds for use in cancer cachexia

Publications (4)

Publication Number Publication Date
JP2021525775A JP2021525775A (ja) 2021-09-27
JPWO2019234402A5 JPWO2019234402A5 (https=) 2022-06-01
JP2021525775A5 true JP2021525775A5 (https=) 2022-06-01
JP7402826B2 JP7402826B2 (ja) 2023-12-21

Family

ID=62872859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567530A Active JP7402826B2 (ja) 2018-06-04 2019-06-03 がん悪液質において用いる化合物

Country Status (11)

Country Link
US (1) US12226387B2 (https=)
EP (1) EP3801490B1 (https=)
JP (1) JP7402826B2 (https=)
KR (1) KR102863322B1 (https=)
CN (1) CN112384211B (https=)
CA (1) CA3102503A1 (https=)
DK (1) DK3801490T3 (https=)
ES (1) ES3014285T3 (https=)
GB (1) GB2575623B (https=)
PL (1) PL3801490T3 (https=)
WO (1) WO2019234402A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12396974B2 (en) 2020-03-27 2025-08-26 KetoneAid Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
CN118591523A (zh) * 2021-11-12 2024-09-03 阿萨达股份公司 多元醇衍生的化合物
KR20250145172A (ko) 2024-03-28 2025-10-13 한림대학교 산학협력단 암 악액질의 예방 또는 치료를 위한 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648952B1 (en) * 2003-06-03 2018-03-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
EP3104396B1 (en) 2003-06-13 2018-03-21 Nikon Corporation Exposure method, substrate stage, exposure apparatus, and device manufacturing method
JP5773870B2 (ja) * 2008-08-21 2015-09-02 アイシス イノヴェイション リミテッド ヒドロキシ酪酸エステル及びその医学的使用
US8642654B2 (en) * 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
JP5269128B2 (ja) 2010-03-12 2013-08-21 エーエスエムエル ネザーランズ ビー．ブイ． リソグラフィ装置および方法
GB201206192D0 (en) * 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
WO2014085652A1 (en) 2012-11-28 2014-06-05 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
GB2515603B (en) 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
WO2018114309A1 (en) * 2016-12-23 2018-06-28 Katholieke Universiteit Leuven 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment

Similar Documents

Publication Publication Date Title
JP2020527547A5 (https=)
JP2021525775A5 (https=)
JP4493337B2 (ja) ３−β−Ｄ−リボフラノシルチアゾロ［４，５−ｄ］ピリミジンヌクレオシド及びその使用
CN105085592B (zh) N-[(2`r)-2`-脱氧-2`-氟-2`-甲基-p-苯基-5`-尿苷酰基]-l-丙氨酸1-甲基乙基酯及其制备方法
WO1994009020A1 (fr) Nouveau shingoglycolipide et son utilisation
JPWO2009119692A1 (ja) 新規糖脂質及びその用途
US12109222B2 (en) Methods and compositions for treating mucositis
JPS63275598A (ja) デスアザプリン―ヌクレオシド―誘導体
CN105646629A (zh) L-核苷类化合物及其应用
CN108289931A (zh) 4’-取代的核苷逆转录酶抑制剂及其制备
CN114450009A (zh) 用于治疗肝脏疾病的尿苷磷酸化酶(upase)抑制剂
WO2015101183A1 (zh) 尿嘧啶核苷酸类似物及其制备方法和应用
US20220008422A1 (en) Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease
JP2022504207A5 (https=)
US20140031309A1 (en) Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases
CN105307680B (zh) 用于作为佐剂使用的β-糖脂
JP5574432B2 (ja) エステル化α−ガラクトシルセラミド類
JPWO2019234402A5 (https=)
JP2002515892A (ja) サイトカインが関係する疾患治療法
US9062088B2 (en) CDK-inhibiting pyrrolopyrimidine carboxamide derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing the same as active ingredient for preventing or treating hepatocellular carcinoma
De et al. Synthesis of a 3′-Fluoro-3′-deoxytetrose Adenine Phosphonate
CN111918870A (zh) 氘代的低聚核苷酸及前体药物
JPWO2020070506A5 (https=)
CA2441806A1 (en) Inosine compounds and their use for treating or preventing an inflammation or a reperfusion disease
KR20240052801A (ko) 플라비바이러스 치료를 위한 2'-클로로-2'-플루오로-n2-아미노-n6-메틸아미노 퓨린 뉴클레오티드